Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Other Non-Current Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 3.61% to $7.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 3.61% increase, with the full-year FY2025 number at $7.2 million, up 3.61% from a year prior.
  • Other Non-Current Liabilities was $7.2 million for Q4 2025 at Lexicon Pharmaceuticals, down from $7.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $7.5 million in Q3 2025 to a low of $5.2 million in Q2 2025.
  • A 3-year average of $6.1 million and a median of $5.7 million in 2023 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: surged 31.51% in 2024, then decreased 13.35% in 2025.
  • Lexicon Pharmaceuticals' Other Non-Current Liabilities stood at $5.3 million in 2023, then surged by 31.51% to $6.9 million in 2024, then rose by 3.61% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Other Non-Current Liabilities are $7.2 million (Q4 2025), $7.5 million (Q3 2025), and $5.2 million (Q2 2025).